Effects of paraoxonase activity and gene polymorphism on coronary vasomotion

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-7

  Dunet, Vincent ^a   Ruiz, Juan ^a   Allenbach, Gilles ^a   Izzo, Paola ^a   James, Richard W ^b   Prior, John O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b University Hospital   (Switzerland)

Author keywords

Diabetes; Myocardial flow reserve; Paraoxonase; Rubidium 82

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; RUBIDIUM 82;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; COLD PRESSOR TEST; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; FRACTIONAL FLOW RESERVE; GENOTYPE; HEART MUSCLE BLOOD FLOW; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 84873985108     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-27     Document Type: Article

References (21)

1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 1986, 256:2835-2838
2. Blatter MC, James RW, Messmer S, Barja F, Pometta D: Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993, 211:871-879.
3. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P: Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
4. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997, 122:265-268.
5. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001, 21:1451-1457.
6. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M: Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 2003, 107:2775-2779.
7. Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P, Jokela H, Laakso J, Jaakkola O, Solakivi T, Lehtimaki T: Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001, 79:449-458.
8. Yildiz A, Gur M, Yilmaz R, Demirbag R, Polat M, Selek S, Celik H, Erel O: Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008, 197:257-263.
9. Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J: Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 2001, 44:104-107.
10. James RW, Leviev I, Righetti A: Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000, 101:2252-2257.
11. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA: Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007, 34:1765-1774.
12. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
13. Acampa W, Di Taranto MD, Morgante A, Salvatore B, Evangelista L, Ricci F, Costanzo P, de Sisto E, Filardi PP, Petretta M, Fortunato G, Cuocolo A: Creactive protein levels are associated with paraoxonase polymorphism L55M in patients undergoing cardiac SPECT imaging. Scandinavian journal of clinical and laboratory investigation 2011, 71:179-184.
14. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A: Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004, 39:59-66.
15. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA: Long-term prognostic value of 13Nammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009, 54:150-156.
16. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, Ruddy TD, Sarveswaran N, Tee RE, Beanlands RS: Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 2011, 58:740-748.
17. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, Liberatoscioli L, Gnasso A, Schillaci G, Mannarino E: Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005, 183:349-354.
18. Bots ML, Westerink J, Rabelink TJ, de Koning EJ: Assessment of flowmediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2005, 26:363-368.
19. Yoshinaga K, Manabe O, Katoh C, Chen L, Klein R, Naya M, Dekemp RA, Williams K, Beanlands RS, Tamaki N: Quantitative analysis of coronary endothelial function with generator-produced (82)Rb PET: comparison with (15)O-labelled water PET. Eur J Nucl Med Mol Imaging 37:2233-2241.
20. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan M-L, Allayee H, Lusis AJ, Hazen SL: Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
21. Ruparelia N, Digby JE, Choudhury RP: Effects of niacin on atherosclerosis and vascular function. Curr Opin Cardiol 2010.